|By PR Newswire||
|January 14, 2014 07:30 AM EST||
DUBLIN, Jan. 14, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced an updated business structure for its U.S. Specialty Brands business designed to maximize the Company's newly strengthened position in key therapeutic areas and position it for continued long-term growth.
Under its new structure, Actavis' U.S. Specialty Brands business has been refocused as four business units - Women's Health, Urology/Gastroenterology (GI), Dermatology/Established Brands and Business Operations. The Company announced the appointment of Herm Cukier to lead the U.S. Specialty Brands Women's Healthcare category, Charles Sabino, Jr., to lead the U.S. Specialty Brands Urology and GI therapeutic category, and Thomas Griffin, Jr., to lead the Business Operations team. The Company is actively engaged in planning efforts related to the leadership of the U.S. Specialty Brands Dermatology and Established Brands business. The four business unit leaders will report to Tim Callahan, Senior Vice President, Commercial Operations, who reports to Fred Wilkinson, President, Actavis Specialty Brands.
"The significant increase in size and complexity of our U.S. Specialty Brands business, following the acquisition of Warner Chilcott last year, demands that we have the right structure and exceptional leadership team in place to drive our continued commercial success in the future," said Mr. Wilkinson. "We believe this business unit structure will provide the most effective way to manage our larger portfolio, provide deeper product and customer insights and deliver the necessary focus to drive continued growth in each therapeutic category within our U.S. Specialty Brands business."
U.S. Women's Health
Actavis' U.S. Women's Health business is an industry leader with over 90 percent share of voice in oral contraceptives based on IMS Audits and a robust pipeline recently bolstered with the addition of seven new development programs encompassing three near-term launches and more than 10 products in late-stage development. As General Manager, U.S. Women's Health, Mr. Cukier joins Actavis from Bayer, where he served most recently as Vice President, Marketing and Commercial Operations for Women's Healthcare. Prior to his time at Bayer, he held roles as President and CEO of Reverion Pharmaceuticals, a start-up biotech company, General Manager at Schering Plough and Chief Marketing Officer at Organon. Earlier in his career Mr. Cukier held positions of increasing commercial responsibility at Bristol Myers Squibb and Pfizer, and he holds a BSE Degree in Bioengineering from the University of Pennsylvania and a MBA in Marketing and International Business from Columbia Business School. Mr. Cukier adds to Actavis' extensive knowledge of the Women's Health market and brings an exceptional background in U.S. and global commercialization to the Actavis organization.
U.S. Urology & Gastroenterology
Actavis' growing Urology business markets six products in the U.S., including Rapaflo® Androderm® and Enablex®. The Company's Gastroenterology business in the U.S. is led by the Delzicol® and Asacol HD® franchise of products. As General Manager, U.S. Urology and Gastroenterology, Mr. Sabino joins Actavis from Aptalis Pharma, where he most recently served as Vice President, Marketing for the specialty pharmaceutical company focused on Gastroenterology and Cystic Fibrosis treatments. Prior to his time at Aptalis, Mr. Sabino served as Chief Operating Officer for Lipose Corp., a medical device company, and as a Managing Director for Cline, Davis & Mann, the second-largest healthcare advertising agency in the United States. Mr. Sabino also held positions of increasing responsibility within both Pfizer and Novartis, including Executive Director of the Xolair® respiratory franchise, and he has a MBA from Columbia Business School and a BS in Biology from Haverford College. Mr. Sabino brings significant commercial expertise to Actavis' specialty brand business and provides a strong foundation of knowledge for Actavis' new Gastroenterology business.
U.S. Business Operations
Actavis' U.S. Business Operations group will be responsible for all shared commercial functions for the respective U.S. therapeutic business units, including sales operations, sales training, marketing research, sales analytics and managed markets field teams. Mr. Griffin has been with Actavis since 2011 as VP, Sales and Operations for the U.S. Specialty Brands business. Prior to joining Actavis, Mr. Griffin was VP, Sales for Bayer Diabetes Care from 2008 to 2010, and prior to that spent 19 years in the Pfizer sales organization in positions of increasing responsibility, culminating as Senior VP Sales for the Urology-Respiratory Therapeutic Cluster. Mr. Griffin brings exceptional sales leadership, operations and managed markets expertise to this newly created U.S. Business Operations unit.
Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA.
Actavis markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries, and operates a global branded specialty pharmaceutical business focused in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories. Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.
For press release and other company information, visit Actavis' Web site at http://www.actavis.com.
Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Actavis' strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actavis' performance, at times, will differ from its goals and expectations. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the inherent uncertainty associated with financial projections; successful integration of the Warner Chilcott acquisition and the ability to recognize the anticipated synergies and benefits of the Warner Chilcott acquisition; the impact of competitive products and pricing; periodic dependence on a small number of products for a material source of net revenue or income; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance on reasonable terms; market acceptance of and continued demand for Actavis' products; changes in the laws and regulations, including Medicare, Medicaid, and similar laws in foreign countries affecting, among other things, pricing and reimbursement of pharmaceutical products and the settlement of patent litigation; and such other risks and uncertainties detailed in Actavis, Inc.'s periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis plc's Quarterly Report on Form 10-Q for the period ending September 30, 2013. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.
SOURCE Actavis plc
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Aug. 3, 2015 11:30 PM EDT Reads: 242
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Aug. 3, 2015 11:00 PM EDT Reads: 693
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
Aug. 3, 2015 10:45 PM EDT Reads: 219
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Aug. 3, 2015 06:45 PM EDT Reads: 533
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Aug. 3, 2015 05:45 PM EDT
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
Aug. 3, 2015 04:00 PM EDT Reads: 276
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Aug. 3, 2015 03:45 PM EDT
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
Aug. 3, 2015 03:30 PM EDT
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
Aug. 3, 2015 03:15 PM EDT
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Aug. 3, 2015 03:00 PM EDT Reads: 560
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
Aug. 3, 2015 12:30 PM EDT Reads: 208
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
Aug. 3, 2015 09:45 AM EDT Reads: 367
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Aug. 3, 2015 07:30 AM EDT Reads: 193
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
Aug. 2, 2015 06:00 PM EDT Reads: 1,138
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
Aug. 2, 2015 04:00 PM EDT Reads: 436